Brenda Hefti, Senior Vice President and General Counsel at EXELIXIS, INC. (NASDAQ:EXEL), reported transactions involving the company’s common stock on May 15 and May 18, 2026. The executive sold shares totaling $332,641 and disposed of additional shares to cover tax obligations.
On May 18, Ms. Hefti sold 6,625 shares of Exelixis common stock for a total value of $332,641. These sales were executed at prices ranging from $49.84 to $50.51 per share, with a weighted average sale price of $50.21. The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 19, 2025.
Additionally, on May 15, Ms. Hefti disposed of 6,411 shares at $51.10 per share, totaling $327,602. These shares were withheld by Exelixis to satisfy tax liabilities from vesting restricted stock units awarded on March 4, 2022, February 29, 2024, and February 26, 2025.
Following these transactions, Ms. Hefti directly holds 106,762 shares of Exelixis common stock. This includes shares from restricted stock units, performance-based awards, and the employee stock purchase plan. She also holds 5,527 shares indirectly through the Exelixis 401(k) Plan.
Exelixis shares trade near their 52-week high of $51.63, with the company valued at $12.25 billion. In recent news, Exelixis reported strong Q1 2026 results with EPS of $0.87 (beat $0.77) and revenue of $611 million. The company also entered a collaboration with Merck for a phase 3 colorectal cancer trial.
